Question 1

What is Trappsol Cyclo?

Accepted Answer

Trappsol Cyclo is a Other.

Question 2

How often does Trappsol Cyclo appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was Trappsol Cyclo first tracked by Ergen?

Accepted Answer

First tracked on Jun 10, 2026.

Question 4

When was Trappsol Cyclo last mentioned in news?

Accepted Answer

Last active on Jun 10, 2026.

Question 5

What is Trappsol Cyclo's current news sentiment?

Accepted Answer

Aggregate sentiment score: 65 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Trappsol Cyclo in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Trappsol Cyclo?

Accepted Answer

Rafael Holdings completes TransportNPC study (Jun 10, 2026, 6 articles).

Question 8

How did the "Rafael Holdings completes TransportNPC study" event impact Trappsol Cyclo?

Accepted Answer

Trappsol Cyclo is the lead candidate being evaluated in the TransportNPC study for Niemann-Pick Disease Type C. The completion of the Phase 3 study and positive pediatric sub-study data highlight its potential as a therapeutic option.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.